Slaughter and May is advising Immunocore on a collaboration with the Bill & Melinda Gates Foundation

Slaughter and May is advising Immunocore Limited, the world’s leading T cell receptor (“TCR”) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, on a collaboration with the Bill & Melinda Gates Foundation.

Under the terms of the collaboration, the Foundation will invest up to $40 million to support development of Immunocore’s ImmTAV™ (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB™ (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics for infectious diseases that pose a global health challenge. The collaboration will discover and develop ImmTAV and ImmTAB molecules for the treatment of human immunodeficiency virus (HIV) and tuberculosis (TB), where the TCR-based therapeutics have the potential to reduce treatment timelines and improve patient outcomes.

The investment by the Foundation was made as part of its programme-related investments (PRI) strategy, which aims to stimulate private sector-driven innovation, encourage market-driven efficiencies and attract external capital to priority global health and development initiatives that improve the lives of the world’s most vulnerable people.

Richard Smith Partner
Claire Jackson Partner
Richard McDonnell Senior Counsel